NCT02816164View on ClinicalTrials.gov

A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia

PHASE4CompletedINTERVENTIONAL
Enrollment

324

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Early Stage Breast Cancer
Interventions
DRUG

Neupogen

Subcutaneous injections

Trial Locations (1)

Unknown

The Ottawa Hospital Research Institute, Ottawa

Sponsors
All Listed Sponsors
lead

Ottawa Hospital Research Institute

OTHER

NCT02816164 - A Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Febrile Neutropenia | Biotech Hunter | Biotech Hunter